HIV vaccine shows some success in Thailand

A Phase III clinical trial involving more than 16,000 adult volunteers in Thailand has demonstrated that an investigational HIV vaccine regimen was safe and modestly effective in preventing HIV infection.

According to final results released by the trial sponsor, the U.S. Army Surgeon General, the prime boost combination of ALVAC® HIV and AIDSVAX® B/E lowered the rate of HIV infection by 31.2% compared with placebo.

"This milestone is the first sign from a study in humans that it is possible to develop an effective HIV vaccine," said Larry Corey, M.D., Co-Director of the Vaccine and Infectious Disease Institute at Fred Hutchinson Cancer Research Center, and the Principal Investigator of the HIV Vaccine Trials Network (HVTN).

HVTN is an international collaboration of scientists and educators searching for an effective and safe HIV vaccine and includes Vanderbilt University's HIV Vaccine Program and the researchers who conducted the study in Thailand.

In the final analysis, 74 placebo recipients became infected with HIV compared to 51 in the vaccine regimen arm. The efficacy result is statistically significant. The vaccine regimen had no effect on the amount of virus in the blood of volunteers who became HIV-infected during the study. More detailed results of this study will be presented next month at the AIDS Vaccine Conference, Oct. 19 through 22 in Paris, France.

Kyle Rybczyk, FNP, RN, program coordinator of Vanderbilt University's HIV Vaccine Program, said the finding is important to the design of future HIV vaccines and how they are tested, however additional research is needed to better understand how this vaccine regimen reduced the risk of HIV infection.

"Every study offers more understanding, but putting it all together is the difficult task at hand," Rybczyk said. "The results won't have immediate implications for the HIV Vaccine trials at Vanderbilt. The HIV Vaccine Trials Network will look at data as it continues to be released and make decisions about the utility of the vaccines and what the future path will be for our network."

Vanderbilt is currently enrolling participants in its HVTN 505 trial which targets men who have sex with men, a group that is disproportionately affected by HIV. 

The Thai trial used two vaccines (ALVACR HIV and AIDSVAXR B/E) that were matched to the strain of HIV that is predominant in Thailand (Clade E). The study had hypothesized that the vaccine would reduce HIV acquisition by 50 percent. Corey said the study results were statistically significant, although they did not reach the level that had been specified.

"While these results are not at the level we will need to effectively control the AIDS pandemic, it is an indication that scientists will reach the goal of developing an effective HIV vaccine," Corey said. "There are several other vaccine candidates in the research pipeline and today's encouraging results will provide renewed enthusiasm for human clinical trials, as well as additional HIV vaccine discovery."

WhistlePig + Alfa Romeo F1

SHOREHAM, VT (September 13, 2023) — WhistlePig Whiskey, the leaders in independent craft whiskey, and Alfa Romeo F1 Team Stake are waving the checkered flag on a legend-worthy release that’s taking whiskey to G-Force levels. The Limited Edition PiggyBack Legends Series: Alfa Romeo F1 Team Stake Barrel is a high Rye Whiskey selected by the Alfa Romeo F1 Team Stake drivers, with barrels trialed in their wind tunnel to ensure a thrilling taste in every sip.

The third iteration in WhistlePig’s Single Barrel PiggyBack Legends Series, the Alfa Romeo F1 Team Stake Barrel is bottled at 96.77 proof, a nod to Valtteri Bottas’ racing number, 77, and the precision of racing. Inspired by Zhou Guanyu, the first Chinese F1 driver, this Rye Whiskey is finished with lychee and oolong tea. Herbal and floral notes of the oolong tea complement the herbaceous notes of WhistlePig’s signature PiggyBack 100% Rye, rounded out with a juicy tropical fruit finish and a touch of spice.

Keep readingShow less
by Spectrum Medical Care Center

Nurse Practitioner Ari Kravitz

When I started medical transition at 20 years old, it was very difficult to get the care I needed for hormone replacement therapy because there are very few providers trained in starting hormones for trans people, even though it’s very similar to the hormones that we prescribe to women in menopause or cisgender men with low testosterone.

I hope more providers get trained in LGBTQ+ healthcare, so they can support patients along their individual gender journey, and provide the info needed to make informed decisions about their body. I’ve personally seen my trans patients find hope and experience a better quality of life through hormone replacement therapy.

Keep readingShow less

Descanso Resort swimming pool and lounge area

Descanso Resort, Palm Springs' premier destination for gay men, just received Tripadvisor's highest honor, a Travelers' Choice "Best of the Best" award for 2023. Based on guests' reviews and ratings, fewer than 1% of Tripadvisor's 8 million listings around the world receive the coveted "Best of the Best" designation. Descanso ranked 12th in the top 25 small inns and hotels category in the United States. Quite an accomplishment!

Open less than two years, Descanso Resort offers gay men a relaxing and luxurious boutique hotel experience just minutes away from Palm Springs' buzziest restaurants, nightclubs, and shopping. Descanso has quickly established itself as a top destination for sophisticated gay travelers, earning hundreds of 5-star guest reviews and consistently ranking in Trapadvisor's top positions alongside brother properties Santiago Resort and Twin Palms Resort.

Keep readingShow less